Results of SUSTAIN Phase III trial of semaglutide for type 2 diabetes- Novo Nordisk

Findings from the first phase IIIa clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue from Novo Nordisk, demonstrated that treatment with semaglutide administered once-weekly, significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone.

Results from the SUSTAIN 1 trial were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US. The 30-week SUSTAIN 1 trial, evaluating the efficacy and safety of semaglutide monotherapy vs placebo in 388 adults with type 2 diabetes, showed that, from a mean baseline HbA1c of 8.1%, adults treated with 0.5 mg and 1.0 mg semaglutide achieved significantly greater HbA1c reductions of 1.5% and 1.6%, respectively, vs less then 0.1% with placebo. In addition, more adults treated with 0.5 mg and 1.0 mg semaglutide achieved HbA1c targets compared with placebo: HbA1c less than 7% (74% and 72% vs 25%). The trial also demonstrated that adults treated with 0.5 mg and 1.0 mg semaglutide achieved significantly greater reductions from baseline in mean body weight of 3.7 kg/8.16 lb and 4.5 kg/9.92 lb, respectively, vs 1.0 kg/2.20 lb with placebo.